Creabilis is a clinical-stage, specialty pharmaceutical company focusing on the development of innovative, first-in-class topical treatments in the field of dermatology. The Company’s lead product, CT327, is a Phase III-ready topical treatment for chronic pruritus (itch), which the Company believes…
Creabilis is a clinical-stage, specialty pharmaceutical company focusing on the development of innovative, first-in-class topical treatments in the field of dermatology.
The Company’s lead product, CT327, is a Phase III-ready topical treatment for chronic pruritus (itch), which the Company believes is the most advanced, novel, topical treatment in development for the indication. Pruritus is a debilitating symptom of many dermatological diseases, with a significant negative impact on a patient’s quality of life.
Team (1)
Sectors Creabilis LTD serves:
Life Sciences
Join Axial's Private M&A Platform
Creabilis LTD connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
